← Back to Search

Alpha-1 Adrenergic Blocker

Open-label treatment with Prazosin for Anxiety Disorders

Phase 1
Waitlist Available
Led By Jitender Sareen, MD
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up to be assessed at baseline, and at weeks 2, 3, 4, 5, 6, 7, 8
Awards & highlights

Summary

Prazosin has shown effectiveness in treating Post-Traumatic Stress Disorder through improving sleep quality and global functioning. Given the significant evidence for its utility in treating PTSD, in combination with the fact that many anxiety symptoms overlap with PTSD (e.g.insomnia, hyperarousal, and irritability), it is essential to evaluate its potential effectiveness in treating symptoms of other anxiety disorder and patient tolerability.

Eligible Conditions
  • Anxiety Disorders
  • Anxiety

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~to be assessed at baseline, and at weeks 2, 3, 4, 5, 6, 7, 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and to be assessed at baseline, and at weeks 2, 3, 4, 5, 6, 7, 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Anxiety Symptoms
Secondary outcome measures
Change in Depressive Symptoms
Change in Level of Disability
Change in Overall Symptom Severity
+5 more

Side effects data

From 2017 Phase 4 trial • 20 Patients • NCT02199652
20%
fainting
10%
psychiatric hospitalization
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Prazosin

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open-label treatment with PrazosinExperimental Treatment1 Intervention
Week 1 Day 1-3: 0.5 mg at bedtime Day 4-7: 1.0 mg at bedtime Week 2 Day 8-10: 2.0 mg at bedtime Day 11-14: 4.0 mg at bedtime Week 3 2 mg in the morning, 4 mg at bedtime Week 4 4 mg in the morning, 4 mg at bedtime Week 5 4 mg in the morning, 6 mg at bedtime Week 6 4 mg in the morning, 8 mg at bedtime Dosage of Prazosin will be titrated at the discretion of the study physician.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prazosin
FDA approved

Find a Location

Who is running the clinical trial?

University of ManitobaLead Sponsor
612 Previous Clinical Trials
201,534 Total Patients Enrolled
5 Trials studying Anxiety Disorders
339 Patients Enrolled for Anxiety Disorders
Jacquelyne Wong, MAStudy DirectorUniversity of Manitoba
1 Previous Clinical Trials
60 Total Patients Enrolled
1 Trials studying Anxiety Disorders
60 Patients Enrolled for Anxiety Disorders
Jitender Sareen, MDPrincipal InvestigatorUniversity of Manitoba
3 Previous Clinical Trials
115 Total Patients Enrolled
1 Trials studying Anxiety Disorders
60 Patients Enrolled for Anxiety Disorders
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top